BCL-2: Long and winding path from discovery to therapeutic target
Details
Publication Year 2017-01-15, Volume 482, Issue #3, Page 459-469
Journal Title
Biochem Biophys Res Commun
Publication Type
Journal Article
Abstract
In 1988, the BCL-2 protein was found to promote cancer by limiting cell death rather than enhancing proliferation. This discovery set the wheels in motion for an almost 30 year journey involving many international research teams that has recently culminated in the approval for a drug, ABT-199/venetoclax/Venclexta that targets this protein in the treatment of cancer. This review will describe the long and winding path from the discovery of this protein and understanding the fundamental process of apoptosis that BCL-2 and its numerous homologues control, through to its exploitation as a drug target that is set to have significant benefit for cancer patients.
Publisher
Elsevier
WEHI Research Division(s)
Molecular Genetics Of Cancer; Cell Signalling And Cell Death
PubMed ID
28212732
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2017-04-06 09:27:24
Last Modified: 2017-04-10 10:01:39
An error has occurred. This application may no longer respond until reloaded. Reload 🗙